πππThe Battle for Weight Loss Drug Supremacy is currently the domain of $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$. It is a huge USD 80 billion market globally. But soon there will be others trying to get a share of this lucrative weight loss market. I am optimistic on $Viking Therapeutics(VKTX)$ as it shows great promise due to its clinical trials. Already Viking Therapeutics Share price has jumped 257% year todate. I believe it can go higher once its drug is approved by the FDA.
LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?
Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading.
Novo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss.
------------
Which weight loss drug company is a better buy?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments